Phosphorus Adsorption Effect and the Influence on Iron-Related Benefit of Sucroferric Oxyhydroxide in Dialysis
- VernacularTitle:人工透析におけるスクロオキシ水酸化鉄のリン吸着効果および鉄関連値への影響
- Author:
Fumitaka OHASHI
1
;
Soshu TANAKA
1
;
Yuta OCHI
1
;
Takuya MARUYAMA
1
;
Haruka GOTO
1
;
Noriko KAYA
1
;
Hirokazu TABATA
1
;
Yasuhiro INAGAKI
1
;
Ryuji KOTERA
1
;
Akio SHIBANAMI
1
Author Information
- From:Journal of the Japanese Association of Rural Medicine 2019;68(2):148-154
- CountryJapan
- Language:Japanese
- Abstract: In hemodialysis, an adsorbent is used to remove phosphorus from the blood.Because phosphorus adsorbents contain iron, they may cause iron excess, and appropriate management is thus required.In recent years, the use of sucroferric oxyhydroxide (SO), which has become available, is said to be associated with lower iron absorption and is less likely to cause iron excess, as compared with conventional ferric citrate hydrate (FCH). However, in clinical trials of SO conducted in Japan, serum ferritin (Ft) and transferrin saturation (TSAT) tended to increase, and this may cause iron excess similar to FCH. Therefore, we report here on the phosphorus adsorption effect and the influence on iron-related benefit of SO.Among 12 patients, iron-related abnormalities were observed in 3 patients and adverse events such as diarrhea and nausea were observed in 7 patients.In 8 patients who continued taking SO for up to 24 weeks, serum phosphorus (P) decreased, Ft and TSAT increased, Hb, Fe, Ca did not change significantly, and the dose of erythropoiesis-stimulating agents (ESA) decreased. The rate of change of Ft was greater in 5 patients with iron deficiency than in 3 patients with non-ferrous deficiency. SO administration tended to decrease P and improve iron deficiency.In addition, there was a decrease in the dose of ESA, suggesting the possibility of contributing to pharmaceutical cost reduction.Conversely, in patients with iron deficiency, iron-related abnormalities were observed in 3 patients, and about half had adverse events with subjective symptoms 4 weeks after the start of treatment with SO.Therefore, the administration of SO takes into account the effects on iron-related values as well as FCH, it is thus considered important to adjust the dose of SO or ESA depending on the condition while monitoring clinical laboratory values and adverse events from the beginning of administration.
